Nanobody-TurboID Maps the CD38 Surfaceome

Cell-surface proteins function within spatially organized neighborhoods rather than as isolated molecular entities. The 2026 study by Feng and colleagues, Exploring the CD38-associated surfaceome via nanobody-targeted TurboID, addresses this problem by developing a proximity-labeling platform for identifying proteins near CD38 in living cells. The work is available as a Molecular & Cellular Proteomics journal pre-proof and can be cited through the reference study.

Study Background and Research Question

CD38 is a cell-surface glycoprotein with enzymatic and signaling functions connected to NAD⁺ metabolism, adhesion, migration, and interactions with the extracellular environment. These activities depend partly on the proteins that surround CD38 within the plasma membrane. Conventional affinity purification can identify stable protein complexes, but it may miss transient, weak, or spatially restricted associations. It can also disrupt membrane organization during cell lysis.

The central question was therefore not simply which proteins bind CD38, but which proteins occupy the CD38-proximal surface environment under relatively native conditions. The authors also asked whether this neighborhood differs between cellular contexts and whether it contains components relevant to tumor-cell adhesion and movement across endothelial layers.

Key Innovation from the Reference Study

The principal innovation is nanobody-targeted TurboID, abbreviated NBID. The method uses a protein-of-interest-specific nanobody fused to the promiscuous biotin ligase TurboID, creating a nanobody-TurboID chimera (NTC). After the chimera is directed to a surface protein such as CD38, TurboID biotinylates nearby proteins. Those labeled proteins can then be captured by affinity enrichment and identified by liquid chromatography-tandem mass spectrometry.

This design offers an important conceptual advantage: spatial proximity is recorded before cell lysis. The method is therefore suited to membrane neighborhoods that are dynamic, heterogeneous, or difficult to preserve biochemically. Rather than claiming that every detected protein directly binds CD38, NBID defines a candidate molecular environment for further validation.

The authors first evaluated the strategy with an EGFR-targeting NTC and recovered several known EGFR-associated proteins. This validation step established that the targeting format could enrich biologically credible surface neighbors before it was applied to CD38. The CD38-specific construct was then used in A549 lung cancer cells and THP-1 monocytic leukemia cells, enabling comparison of CD38-proximal protein profiles in distinct cellular backgrounds.

Methods and Experimental Design Insights

Cell models and proteomic workflow

The study combined targeted proximity labeling with affinity capture and LC-MS/MS. In broad terms, living cells expressing the relevant NTC were exposed to the labeling workflow, lysed, and processed to enrich biotinylated proteins. The resulting peptide mixtures were analyzed by mass spectrometry to identify proteins whose abundance was increased in the CD38-targeted condition relative to appropriate controls.

The use of both A549 and THP-1 cells was informative because it separated features likely to be broadly associated with CD38 from features that may depend on epithelial tumor-cell state, myeloid-lineage context, or differences in membrane organization. The authors also examined whether NAD⁺ treatment altered the CD38-proximal surfaceome in A549 cells. Total internal reflection fluorescence microscopy (TIRFM) supplied an imaging-based test of whether selected candidates occupied the same membrane protrusions as CD38.

Intercellular proximity labeling and functional testing

A further experimental layer used stable isotope labeling by amino acids in cell culture (SILAC). Light and heavy cell populations were combined for comparative proteomics, allowing the researchers to investigate protein neighborhoods associated with contact between tumor cells and endothelial cells. This design was particularly relevant to transendothelial migration, in which adhesion complexes must operate at a tumor–endothelial interface.

Functional assays complemented the proteomic results. Instead of treating enrichment as proof of biological importance, the authors tested the effect of CD38 on A549 transendothelial migration. This progression from molecular discovery to spatial imaging and cell behavior is a strength of the study because it connects a surfaceome signature with a measurable phenotype.

Protocol Parameters

• Targeting construct: use a POI-specific nanobody-TurboID chimera and include a targeting control, with EGFR serving as the study’s validation example.
• Labeling context: perform proximity labeling in living adherent cells so that membrane organization and short-lived neighborhoods are sampled before lysis.
• Proteomic readout: combine affinity capture of biotinylated proteins with trypsin digestion and LC-MS/MS identification; use quantitative comparisons rather than isolated peptide detections.
• Cellular comparison: evaluate the construct in more than one biologically relevant cell model when the objective is to distinguish shared CD38 features from cell-state-specific associations.
• Orthogonal validation: use TIRFM or another spatial imaging method to examine candidate co-clustering, and pair the molecular data with a functional migration or adhesion assay.
• Intercellular analysis: apply SILAC or another quantitative design when the question concerns protein neighborhoods formed at a tumor–endothelial interface.

Core Findings and Why They Matter

CD38-targeted NBID enriched proteins involved in cell adhesion, extracellular-matrix organization, and lipid-raft-associated membrane domains in both A549 and THP-1 cells, according to the published study record and pre-proof findings. This pattern supports the view that CD38 is positioned within broader membrane systems that can influence cell attachment, receptor organization, and communication with the extracellular matrix.

A549 cells showed additional enrichment of proteins associated with Wnt signaling. That result should be interpreted as a context-dependent feature of the A549 CD38 neighborhood rather than as evidence that CD38 universally activates a Wnt program. It illustrates why surface-proximity measurements in multiple cell types are valuable: the same target can occupy different functional networks depending on lineage, oncogenic state, and membrane architecture.

NAD⁺ treatment did not significantly change the CD38-proximal surfaceome in A549 cells under the tested conditions. This negative result is useful because it places a boundary around the interpretation of CD38-associated metabolism. Changes in CD38 enzymatic substrate availability do not necessarily produce an immediate, global rearrangement of its detectable surface neighborhood.

TIRFM showed that several enriched candidates co-clustered with CD38 on membrane protrusions. The imaging result provides spatial support for the proteomic data, although co-localization remains distinct from direct physical binding. The candidate set included proteins such as CDH2, Nectin-2, FZD2, PRNP, and CRIM1 in A549-associated analyses, while the broader NBID dataset also included adhesion-related proteins such as MRC2, CD99, CTNNB1, and DSG2.

The intercellular SILAC experiments further implicated cadherin adhesion complexes involving CDH2 and DSG2 at the tumor–endothelial interface. In functional experiments, CD38 contributed to A549 transendothelial migration. Together, these findings connect CD38-proximal adhesion networks with a tumor-cell behavior that is relevant to vascular crossing and metastatic dissemination. The study does not establish a single linear pathway; instead, it presents CD38 as a component of a membrane adhesion network whose organization may influence migration.

Comparison with Existing Internal Articles

The internal article CFDA-SE for Cell Proliferation Tracking describes a different type of measurement: a division-sensitive fluorescent signal that reports the proliferation history of viable cells. A related workflow guide, CFDA-SE Workflows for Proliferation Tracking, emphasizes that proliferation labeling should not be confused with a molecular interaction map.

That distinction is important when interpreting the CD38 study. NBID identifies proteins in a spatially proximal surface environment, whereas a CFDA-SE-based lymphocyte proliferation assay, fibroblast proliferation monitoring, natural killer cell proliferation experiment, or bacterial proliferation assay measures dilution of fluorescence through cell division. The approaches can be complementary in a broader experiment, but neither is a substitute for the other: surfaceome mapping addresses molecular neighborhood, while fluorescence dilution addresses population expansion and division history.

Limitations and Transferability

NBID records proximity, not necessarily direct interaction, enzymatic dependence, or stable complex membership. TurboID labeling can also reflect the effective labeling radius, reaction timing, expression level of the chimera, and accessibility of the targeted epitope. Nanobody binding itself may influence receptor organization, particularly for a surface protein involved in adhesion. Appropriate controls are therefore essential for distinguishing specific enrichment from labeling background or construct-induced clustering.

The biological scope is also limited. The main models were A549 and THP-1 cells, and the migration experiments focused on A549 behavior. Findings from these systems should not automatically be transferred to primary tumor cells, normal epithelial cells, endothelial cells, or immune populations without replication. The lack of a major NAD⁺-dependent change in A549 cells is similarly conditional on the treatment and culture context used in the study.

Finally, the work is presented as a journal pre-proof. Its conclusions are substantial, but readers should consult the definitive version for any changes introduced during copyediting, typesetting, or final review. Future applications should validate candidates using independent perturbation, biochemical interaction assays, or loss-of-function experiments rather than relying on proximity enrichment alone.

Why this cross-domain matters, maturity, and limitations

Pairing a surface-proximity map with a division-history measurement can help separate altered migration or adhesion from simple differences in cell expansion. However, this is a complementary experimental strategy, not a conclusion demonstrated directly by the reference study. A proliferation tracer can provide an orthogonal phenotypic covariate, but it cannot identify CD38 neighbors, prove a cadherin interaction, or replace NBID, imaging, and migration controls.

Research Support Resources

For experiments that need an independent record of viable-cell division alongside CD38 surfaceome or migration studies, researchers can use CFDA-SE (Carboxyfluorescein diacetate succinimidyl ester), SKU C3430. This fluorescent cell-labeling reagent is converted by intracellular esterases into CFSE, which is retained through intracellular amine coupling and diluted as cells divide. The product information reports fluorescence excitation at 494 nm and emission at 521 nm and notes that staining concentrations commonly vary by cell type; these parameters should be optimized independently of the NBID labeling design.